GlassScriptPhysician profile
Ryan Michael Aschenbrener
NPI 1649702317
$8,461.13
in general payments reported to CMS, 2019-2025
22 companies · $3,040 in 2025
The $3,040 reported for 2025 was more than what 96% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,356 · 2022: $1,831 · 2023: $726 · 2024: $1,508 · 2025: $3,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,596 · Travel and Lodging: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,595.97 |
| Travel and Lodging | $677.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $1,516.58 | 2025 | Senza, Omnia |
| Abbott Laboratories | $968.48 | 2021-2025 | Eterna, Proclaim |
| Biotronik Nro, INC. | $961.39 | 2023-2025 | Prospera, Biotronik |
| Mml US, INC. | $905.90 | 2021 | |
| Medtronic, INC. | $878.41 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $685.41 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $441.08 | 2022-2025 | Belbuca, Xtampza |
| Nalu Medical, INC. | $331.89 | 2021-2022 | |
| Saluda Medical Americas, INC. | $295.19 | 2023-2025 | Evoke, Evoke Scs |
| Scilex Pharmaceuticals INC. | $277.97 | 2022-2025 | Ztlido |
| Bioventus LLC | $232.56 | 2021-2022 | |
| Relievant Medsystems, INC. | $201.17 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $152.69 | 2024-2025 | Levorphanol Tartrate |
| Averitas Pharma INC. | $131.24 | 2023-2024 | Qutenza |
| Nevro Corp. | $113.89 | 2022-2024 | Senza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $102.57 | 2022-2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $74.46 | 2024-2025 | |
| Si-Bone, INC. | $68.23 | 2022-2023 | |
| Spr Therapeutics, INC | $35.04 | 2021 | |
| Ibsa Pharma INC. | $34.72 | 2023-2025 | Tirosint, Tirosint, Flector |
| Protega Pharmaceutials INC | $30.07 | 2024 | Roxybond |
| Forte Bio-Pharma LLC | $22.19 | 2024 | Prolate, Nalocet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Aschenbrener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.